{
    "guideline": {
        "id": "PA166104969",
        "name": "Annotation of DPWG Guideline for flecainide and CYP2D6",
        "source": "DPWG",
        "version": 33,
        "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166104969",
        "relatedChemicals": [
            {
                "id": "PA449646",
                "name": "flecainide",
                "symbol": null
            }
        ],
        "relatedGenes": [
            {
                "id": "PA128",
                "name": "cytochrome P450 family 2 subfamily D member 6",
                "symbol": "CYP2D6"
            }
        ],
        "recommendation": true
    },
    "recommendations": [
        {
            "id": "PA166302392",
            "name": "Recommendation Annotation PA166302392",
            "population": null,
            "classification": {
                "term": "N/A",
                "termId": "guidelineStrength:981501929"
            },
            "relatedChemicals": [
                {
                    "id": "PA449646",
                    "name": "flecainide",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452103971,
                "html": "<p>There are no data about the pharmacokinetics and/or the effects of flecainide in UM. Monitor the plasma concentration as a precaution and record an ECG or select an alternative. Examples of anti-arrhythmic drugs that are not metabolized via CYP2D6 (or to a lesser extent) include sotalol, disopyramide, quinidine and amiodarone.</p>\n"
            },
            "implications": [
                "The genetic variation increases conversion of flecainide to inactive metabolites. A higher dose is possibly required as a result."
            ],
            "lookupKey": {
                "CYP2D6": "4.0"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": true,
            "guidanceLevel": "2"
        },
        {
            "id": "PA166302383",
            "name": "Recommendation Annotation PA166302383",
            "population": null,
            "classification": {
                "term": "N/A",
                "termId": "guidelineStrength:981501929"
            },
            "relatedChemicals": [
                {
                    "id": "PA449646",
                    "name": "flecainide",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452103962,
                "html": "<p>Indications other than diagnosis of Brugada syndrome:</p>\n<ul>\n<li>Reduce the dose to 75% of the standard dose and record an ECG and monitor the plasma concentration.</li>\n</ul>\n<p>Provocation test for diagnosis of Brugada syndrome:</p>\n<ul>\n<li>No action required. At a dose of 2.0 mg/kg body weight to a maximum of 150 mg, the response is better for patients with alleles that result in reduced activity. All 5 patients with these alleles and 20% of the patients with two fully active alleles exhibited a response within 30 minutes.</li>\n</ul>\n"
            },
            "implications": [
                "The genetic variation reduces conversion of flecainide to inactive metabolites. This may increase the risk of side effects."
            ],
            "lookupKey": {
                "CYP2D6": "0.5"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "2"
        },
        {
            "id": "PA166302396",
            "name": "Recommendation Annotation PA166302396",
            "population": null,
            "classification": {
                "term": "N/A",
                "termId": "guidelineStrength:981501929"
            },
            "relatedChemicals": [
                {
                    "id": "PA449646",
                    "name": "flecainide",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452103975,
                "html": "<p>There are no data about the pharmacokinetics and/or the effects of flecainide in UM. Monitor the plasma concentration as a precaution and record an ECG or select an alternative. Examples of anti-arrhythmic drugs that are not metabolized via CYP2D6 (or to a lesser extent) include sotalol, disopyramide, quinidine and amiodarone.</p>\n"
            },
            "implications": [
                "The genetic variation increases conversion of flecainide to inactive metabolites. A higher dose is possibly required as a result."
            ],
            "lookupKey": {
                "CYP2D6": "\u22654.0"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": true,
            "guidanceLevel": "2"
        },
        {
            "id": "PA166302387",
            "name": "Recommendation Annotation PA166302387",
            "population": null,
            "classification": {
                "term": "No recommendation",
                "termId": "guidelineStrength:1448526251"
            },
            "relatedChemicals": [
                {
                    "id": "PA449646",
                    "name": "flecainide",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452103966,
                "html": "<p>The guideline does not provide a recommendation for flecainide in normal metabolizers.</p>\n"
            },
            "implications": [
                "The guideline does not provide a description of the impact of a normal metabolizer phenotype on flecainide."
            ],
            "lookupKey": {
                "CYP2D6": "1.5"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "1"
        },
        {
            "id": "PA166302391",
            "name": "Recommendation Annotation PA166302391",
            "population": null,
            "classification": {
                "term": "N/A",
                "termId": "guidelineStrength:981501929"
            },
            "relatedChemicals": [
                {
                    "id": "PA449646",
                    "name": "flecainide",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452103970,
                "html": "<p>There are no data about the pharmacokinetics and/or the effects of flecainide in UM. Monitor the plasma concentration as a precaution and record an ECG or select an alternative. Examples of anti-arrhythmic drugs that are not metabolized via CYP2D6 (or to a lesser extent) include sotalol, disopyramide, quinidine and amiodarone.</p>\n"
            },
            "implications": [
                "The genetic variation increases conversion of flecainide to inactive metabolites. A higher dose is possibly required as a result."
            ],
            "lookupKey": {
                "CYP2D6": "3.0"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": true,
            "guidanceLevel": "2"
        },
        {
            "id": "PA166302395",
            "name": "Recommendation Annotation PA166302395",
            "population": null,
            "classification": {
                "term": "N/A",
                "termId": "guidelineStrength:981501929"
            },
            "relatedChemicals": [
                {
                    "id": "PA449646",
                    "name": "flecainide",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452103974,
                "html": "<p>There are no data about the pharmacokinetics and/or the effects of flecainide in UM. Monitor the plasma concentration as a precaution and record an ECG or select an alternative. Examples of anti-arrhythmic drugs that are not metabolized via CYP2D6 (or to a lesser extent) include sotalol, disopyramide, quinidine and amiodarone.</p>\n"
            },
            "implications": [
                "The genetic variation increases conversion of flecainide to inactive metabolites. A higher dose is possibly required as a result."
            ],
            "lookupKey": {
                "CYP2D6": "\u22653.5"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": true,
            "guidanceLevel": "2"
        },
        {
            "id": "PA166302382",
            "name": "Recommendation Annotation PA166302382",
            "population": null,
            "classification": {
                "term": "N/A",
                "termId": "guidelineStrength:981501929"
            },
            "relatedChemicals": [
                {
                    "id": "PA449646",
                    "name": "flecainide",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452103961,
                "html": "<p>Indications other than diagnosis of Brugada syndrome:</p>\n<ul>\n<li>Reduce the dose to 75% of the standard dose and record an ECG and monitor the plasma concentration.</li>\n</ul>\n<p>Provocation test for diagnosis of Brugada syndrome:</p>\n<ul>\n<li>No action required. At a dose of 2.0 mg/kg body weight to a maximum of 150 mg, the response is better for patients with alleles that result in reduced activity. All 5 patients with these alleles and 20% of the patients with two fully active alleles exhibited a response within 30 minutes.</li>\n</ul>\n"
            },
            "implications": [
                "The genetic variation reduces conversion of flecainide to inactive metabolites. This may increase the risk of side effects."
            ],
            "lookupKey": {
                "CYP2D6": "0.25"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "2"
        },
        {
            "id": "PA166302386",
            "name": "Recommendation Annotation PA166302386",
            "population": null,
            "classification": {
                "term": "No recommendation",
                "termId": "guidelineStrength:1448526251"
            },
            "relatedChemicals": [
                {
                    "id": "PA449646",
                    "name": "flecainide",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452103965,
                "html": "<p>The guideline does not provide a recommendation for flecainide in normal metabolizers.</p>\n"
            },
            "implications": [
                "The guideline does not provide a description of the impact of a normal metabolizer phenotype on flecainide."
            ],
            "lookupKey": {
                "CYP2D6": "1.25"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "1"
        },
        {
            "id": "PA166302390",
            "name": "Recommendation Annotation PA166302390",
            "population": null,
            "classification": {
                "term": "No recommendation",
                "termId": "guidelineStrength:1448526251"
            },
            "relatedChemicals": [
                {
                    "id": "PA449646",
                    "name": "flecainide",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452103969,
                "html": "<p>The guideline does not provide a recommendation for flecainide in normal metabolizers.</p>\n"
            },
            "implications": [
                "The guideline does not provide a description of the impact of a normal metabolizer phenotype on flecainide."
            ],
            "lookupKey": {
                "CYP2D6": "2.5"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "1"
        },
        {
            "id": "PA166302394",
            "name": "Recommendation Annotation PA166302394",
            "population": null,
            "classification": {
                "term": "N/A",
                "termId": "guidelineStrength:981501929"
            },
            "relatedChemicals": [
                {
                    "id": "PA449646",
                    "name": "flecainide",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452103973,
                "html": "<p>There are no data about the pharmacokinetics and/or the effects of flecainide in UM. Monitor the plasma concentration as a precaution and record an ECG or select an alternative. Examples of anti-arrhythmic drugs that are not metabolized via CYP2D6 (or to a lesser extent) include sotalol, disopyramide, quinidine and amiodarone.</p>\n"
            },
            "implications": [
                "The genetic variation increases conversion of flecainide to inactive metabolites. A higher dose is possibly required as a result."
            ],
            "lookupKey": {
                "CYP2D6": "\u22653.25"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": true,
            "guidanceLevel": "2"
        },
        {
            "id": "PA166302381",
            "name": "Recommendation Annotation PA166302381",
            "population": null,
            "classification": {
                "term": "N/A",
                "termId": "guidelineStrength:981501929"
            },
            "relatedChemicals": [
                {
                    "id": "PA449646",
                    "name": "flecainide",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452103960,
                "html": "<p>Reduce the dose to 50% of the standard dose and record an ECG and monitor the plasma concentration.</p>\n"
            },
            "implications": [
                "The genetic variation reduces conversion of flecainide to inactive metabolites. This increases the risk of side effects."
            ],
            "lookupKey": {
                "CYP2D6": "0.0"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "2"
        },
        {
            "id": "PA166302385",
            "name": "Recommendation Annotation PA166302385",
            "population": null,
            "classification": {
                "term": "N/A",
                "termId": "guidelineStrength:981501929"
            },
            "relatedChemicals": [
                {
                    "id": "PA449646",
                    "name": "flecainide",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452103964,
                "html": "<p>Indications other than diagnosis of Brugada syndrome:</p>\n<ul>\n<li>Reduce the dose to 75% of the standard dose and record an ECG and monitor the plasma concentration.</li>\n</ul>\n<p>Provocation test for diagnosis of Brugada syndrome:</p>\n<ul>\n<li>No action required. At a dose of 2.0 mg/kg body weight to a maximum of 150 mg, the response is better for patients with alleles that result in reduced activity. All 5 patients with these alleles and 20% of the patients with two fully active alleles exhibited a response within 30 minutes.</li>\n</ul>\n"
            },
            "implications": [
                "The genetic variation reduces conversion of flecainide to inactive metabolites. This may increase the risk of side effects."
            ],
            "lookupKey": {
                "CYP2D6": "1.0"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "2"
        },
        {
            "id": "PA166302398",
            "name": "Recommendation Annotation PA166302398",
            "population": null,
            "classification": {
                "term": "N/A",
                "termId": "guidelineStrength:981501929"
            },
            "relatedChemicals": [
                {
                    "id": "PA449646",
                    "name": "flecainide",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452103977,
                "html": "<p>There are no data about the pharmacokinetics and/or the effects of flecainide in UM. Monitor the plasma concentration as a precaution and record an ECG or select an alternative. Examples of anti-arrhythmic drugs that are not metabolized via CYP2D6 (or to a lesser extent) include sotalol, disopyramide, quinidine and amiodarone.</p>\n"
            },
            "implications": [
                "The genetic variation increases conversion of flecainide to inactive metabolites. A higher dose is possibly required as a result."
            ],
            "lookupKey": {
                "CYP2D6": "\u22656.0"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": true,
            "guidanceLevel": "2"
        },
        {
            "id": "PA166302389",
            "name": "Recommendation Annotation PA166302389",
            "population": null,
            "classification": {
                "term": "No recommendation",
                "termId": "guidelineStrength:1448526251"
            },
            "relatedChemicals": [
                {
                    "id": "PA449646",
                    "name": "flecainide",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452103968,
                "html": "<p>The guideline does not provide a recommendation for flecainide in normal metabolizers.</p>\n"
            },
            "implications": [
                "The guideline does not provide a description of the impact of a normal metabolizer phenotype on flecainide."
            ],
            "lookupKey": {
                "CYP2D6": "2.25"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "1"
        },
        {
            "id": "PA166302393",
            "name": "Recommendation Annotation PA166302393",
            "population": null,
            "classification": {
                "term": "N/A",
                "termId": "guidelineStrength:981501929"
            },
            "relatedChemicals": [
                {
                    "id": "PA449646",
                    "name": "flecainide",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452103972,
                "html": "<p>There are no data about the pharmacokinetics and/or the effects of flecainide in UM. Monitor the plasma concentration as a precaution and record an ECG or select an alternative. Examples of anti-arrhythmic drugs that are not metabolized via CYP2D6 (or to a lesser extent) include sotalol, disopyramide, quinidine and amiodarone.</p>\n"
            },
            "implications": [
                "The genetic variation increases conversion of flecainide to inactive metabolites. A higher dose is possibly required as a result."
            ],
            "lookupKey": {
                "CYP2D6": "\u22653.0"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": true,
            "guidanceLevel": "2"
        },
        {
            "id": "PA166302384",
            "name": "Recommendation Annotation PA166302384",
            "population": null,
            "classification": {
                "term": "N/A",
                "termId": "guidelineStrength:981501929"
            },
            "relatedChemicals": [
                {
                    "id": "PA449646",
                    "name": "flecainide",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452103963,
                "html": "<p>Indications other than diagnosis of Brugada syndrome:</p>\n<ul>\n<li>Reduce the dose to 75% of the standard dose and record an ECG and monitor the plasma concentration.</li>\n</ul>\n<p>Provocation test for diagnosis of Brugada syndrome:</p>\n<ul>\n<li>No action required. At a dose of 2.0 mg/kg body weight to a maximum of 150 mg, the response is better for patients with alleles that result in reduced activity. All 5 patients with these alleles and 20% of the patients with two fully active alleles exhibited a response within 30 minutes.</li>\n</ul>\n"
            },
            "implications": [
                "The genetic variation reduces conversion of flecainide to inactive metabolites. This may increase the risk of side effects."
            ],
            "lookupKey": {
                "CYP2D6": "0.75"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "2"
        },
        {
            "id": "PA166302397",
            "name": "Recommendation Annotation PA166302397",
            "population": null,
            "classification": {
                "term": "N/A",
                "termId": "guidelineStrength:981501929"
            },
            "relatedChemicals": [
                {
                    "id": "PA449646",
                    "name": "flecainide",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452103976,
                "html": "<p>There are no data about the pharmacokinetics and/or the effects of flecainide in UM. Monitor the plasma concentration as a precaution and record an ECG or select an alternative. Examples of anti-arrhythmic drugs that are not metabolized via CYP2D6 (or to a lesser extent) include sotalol, disopyramide, quinidine and amiodarone.</p>\n"
            },
            "implications": [
                "The genetic variation increases conversion of flecainide to inactive metabolites. A higher dose is possibly required as a result."
            ],
            "lookupKey": {
                "CYP2D6": "\u22655.0"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": true,
            "guidanceLevel": "2"
        },
        {
            "id": "PA166302388",
            "name": "Recommendation Annotation PA166302388",
            "population": null,
            "classification": {
                "term": "No recommendation",
                "termId": "guidelineStrength:1448526251"
            },
            "relatedChemicals": [
                {
                    "id": "PA449646",
                    "name": "flecainide",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452103967,
                "html": "<p>The guideline does not provide a recommendation for flecainide in normal metabolizers.</p>\n"
            },
            "implications": [
                "The guideline does not provide a description of the impact of a normal metabolizer phenotype on flecainide."
            ],
            "lookupKey": {
                "CYP2D6": "2.0"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "1"
        }
    ],
    "citations": [
        {
            "pmid": "21412232",
            "title": "Pharmacogenetics: from bench to byte--an update of guidelines.",
            "authors": [
                "Swen J J",
                "Nijenhuis M",
                "de Boer A",
                "Grandia L",
                "Maitland-van der Zee A H",
                "Mulder H",
                "Rongen G A P J M",
                "van Schaik R H N",
                "Schalekamp T",
                "Touw D J",
                "van der Weide J",
                "Wilffert B",
                "Deneer V H M",
                "Guchelaar H-J"
            ],
            "journal": "Clinical pharmacology and therapeutics",
            "year": 2011
        }
    ],
    "version": "2024-03-25-16-13"
}